Iressa News and Research

RSS
AI may help predict tumor sensitivity to systemic cancer therapies

AI may help predict tumor sensitivity to systemic cancer therapies

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

RTKI drugs may not significantly improve survival rates of patients during radiotherapy

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

Findings point to potential new treatment for people with newly diagnosed EGFR-positive NSCLC

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca, MedImmune to present new clinical trial and scientific data on lung cancer treatments at ELCC 2016

AstraZeneca presents lung cancer research data at WCLC 2015

AstraZeneca presents lung cancer research data at WCLC 2015

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

QIAGEN's therascreen EGFR RGQ PCR Kit to guide use of IRESSA for in NSCLC treatment

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

Alabama scientists show how phytochemical in magnolia works against head and neck cancers

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

QIAGEN's circulating tumor DNA test CE-IVD marked to assess genomic mutation NSCLC patients

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Mirati begins dosage in MGCD265 Phase 1b clinical trial for NSCLC

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

Commonly used osteoporosis medications may also prevent lung, breast and colon cancers

FDA-approved therapy could be effective in older, African American patients with lung cancer

FDA-approved therapy could be effective in older, African American patients with lung cancer

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AstraZeneca, Pharmacyclics partner to evaluate efficacy of IMBRUVICA for solid tumors

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Acquired resistance to cancer therapies: an interview with Dr Rajendra Kumari, Chief Scientific Officer at PRECOS

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Molecular marker predicts longer survival among patients prescribed two cancer drugs

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Findings suggest that a prosaposin-based drug could block metastasis spread

Findings suggest that a prosaposin-based drug could block metastasis spread

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Sabutoclax appears to selectively target leukemia stem cells that are responsible for relapses

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's

Anti-cancer EGFR inhibitors effective in reversing memory loss in animal models of Alzheimer's